US Patent

US11021475 — Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses

Method of Use · Assigned to Bristol Myers Squibb Co · Expires 2033-11-07 · 7y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compounds useful in modulating IL-12, IL-23, and/or IFN alpha responses by acting on Tyk-2 to cause signal transduction inhibition.

USPTO Abstract

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNÎ±, by acting on Tyk-2 to cause signal transduction inhibition.

Drugs covered by this patent

Sotyktu (DEUCRAVACITINIB) · Bristol-Myers Squibb

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3434`	—	Sotyktu

Patent Metadata

Patent number: US11021475
Jurisdiction: US
Classification: Method of Use
Expires: 2033-11-07
Drug substance claim: No
Drug product claim: No
Assignee: Bristol Myers Squibb Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.